8-K: Foghorn Therapeutics 2026 Annual Meeting Results

Foghorn Therapeutics stockholders re-elected directors and ratified the appointment of Deloitte & Touche LLP at the 2026 Annual Meeting.

Summary

• Foghorn Therapeutics held its 2026 Annual Meeting of Stockholders on June 24, 2026.
• Stockholders elected Douglas Cole, M.D., Balkrishan (Simba) Gill, Ph.D., and B. Lynne Parshall as Class III directors for three-year terms.
• Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
• Stockholders approved the compensation of named executive officers on an advisory basis.
• Stockholders voted in favor of maintaining an annual frequency for future advisory votes on executive compensation.
• A total of 51,708,896 shares were represented at the meeting out of 58,713,922 shares entitled to vote.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the filing reports routine administrative and governance outcomes from an annual meeting.

Positives

• Strong shareholder support for the ratification of the independent auditor with 51,661,238 votes for.
• High approval rating for executive compensation packages.
• Successful election of all nominated Class III directors.

Negatives

• Douglas Cole, M.D. received a significant number of votes against his re-election (10,987,092) compared to other nominees.

Risks

• Potential for continued shareholder scrutiny regarding board composition and executive compensation structures.

Future Outlook

The company will continue to hold annual advisory votes on executive compensation, with the next vote expected in 2027.

Industry Context

StockSavvy.ai notes that this filing represents standard corporate governance procedures for a Nasdaq-listed biotechnology company, reflecting typical shareholder engagement patterns for mid-cap life sciences firms.

Comparison to Industry Standards

• The ratification of auditors and election of directors are consistent with standard practices for U.S. public companies.
• The adoption of an annual 'say-on-pay' frequency aligns with the majority of U.S. public company governance policies.

Corporate Governance

Stakeholder Impact

• Shareholders have confirmed their support for current board leadership and executive compensation policies.

Next Steps

• Conduct the 2027 Annual Meeting of Stockholders.
• Continue financial reporting and audit processes with Deloitte & Touche LLP.

Key Dates

Keywords

Foghorn Therapeutics, FHTX, Annual Meeting, Proxy Voting, Corporate Governance, Biotech